Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Theravance Biopharma Inc and
partner Mylan NV on Friday won U.S. regulatory approval
for their treatment for a chronic lung condition that causes
breathing-related problems.


Source: reuters

Related posts

Leave a Comment